Ochs Nicolas, Auer Reto, Bauer Douglas C, Nanchen David, Gussekloo Jacobijn, Cornuz Jacques, Rodondi Nicolas
University of Lausanne, Lausanne, Switzerland.
Ann Intern Med. 2008 Jun 3;148(11):832-45. doi: 10.7326/0003-4819-148-11-200806030-00225. Epub 2008 May 19.
Data on the association between subclinical thyroid dysfunction and coronary heart disease (CHD) and mortality are conflicting.
To summarize prospective evidence about the relationship between subclinical thyroid dysfunction and CHD and mortality.
MEDLINE (1950 to January 2008) without language restrictions and reference lists of retrieved articles were searched.
Two reviewers screened and selected cohort studies that measured thyroid function and then followed persons prospectively to assess CHD or mortality.
By using a standardized protocol and forms, 2 reviewers independently abstracted and assessed studies.
Ten of 12 identified studies involved population-based cohorts that included 14 449 participants. All 10 population-based cohort studies examined risks associated with subclinical hypothyroidism (2134 CHD events and 2822 deaths), whereas only 5 examined risks associated with subclinical hyperthyroidism (1392 CHD events and 1993 deaths). In a random-effects model, the relative risk (RR) for subclinical hypothyroidism for CHD was 1.20 (95% CI, 0.97 to 1.49; P for heterogeneity = 0.14; I(2 )= 33.4%). Risk estimates were lower when higher-quality studies were pooled (RR, 1.02 to 1.08) and were higher among participants younger than 65 years (RR, 1.51 [CI, 1.09 to 2.09] for studies with mean participant age <65 years and 1.05 [CI, 0.90 to 1.22] for studies with mean participant age > or =65 years). The RR was 1.18 (CI, 0.98 to 1.42) for cardiovascular mortality and 1.12 (CI, 0.99 to 1.26) for total mortality. For subclinical hyperthyroidism, the RR was 1.21 (CI, 0.88 to 1.68) for CHD, 1.19 (CI, 0.81 to 1.76) for cardiovascular mortality, and 1.12 (CI, 0.89 to 1.42) for total mortality (P for heterogeneity >0.50; I(2 )= 0% for all studies).
Individual studies adjusted for different potential confounders, and 1 study provided only unadjusted data. Publication bias or selective reporting of outcomes could not be excluded.
Subclinical hypothyroidism and hyperthyroidism may be associated with a modest increased risk for CHD and mortality, with lower risk estimates when pooling higher-quality studies and larger CIs for subclinical hyperthyroidism.
关于亚临床甲状腺功能障碍与冠心病(CHD)及死亡率之间关联的数据相互矛盾。
总结关于亚临床甲状腺功能障碍与冠心病及死亡率之间关系的前瞻性证据。
检索了无语言限制的MEDLINE(1950年至2008年1月)以及检索到文章的参考文献列表。
两名评审员筛选并选择了测量甲状腺功能并对人员进行前瞻性随访以评估冠心病或死亡率的队列研究。
两名评审员使用标准化方案和表格独立提取并评估研究。
12项已识别研究中的10项涉及基于人群的队列,包括14449名参与者。所有10项基于人群的队列研究均检查了与亚临床甲状腺功能减退相关的风险(2134例冠心病事件和2822例死亡),而只有5项研究检查了与亚临床甲状腺功能亢进相关的风险(1392例冠心病事件和1993例死亡)。在随机效应模型中,亚临床甲状腺功能减退导致冠心病的相对风险(RR)为1.20(95%CI,0.97至1.49;异质性P = 0.14;I² = 33.4%)。合并高质量研究时风险估计值较低(RR,1.02至1.08),在65岁以下参与者中较高(平均参与者年龄<65岁的研究中RR为1.51[CI,1.09至2.09],平均参与者年龄≥65岁的研究中RR为1.05[CI,0.90至1.22])。心血管死亡率的RR为1.18(CI,0.98至1.42),总死亡率的RR为1.12(CI,0.99至1.26)。对于亚临床甲状腺功能亢进,冠心病的RR为1.21(CI,0.88至1.68),心血管死亡率的RR为1.19(CI,0.81至1.76),总死亡率的RR为1.12(CI,0.89至1.42)(异质性P>0.50;所有研究的I² = 0%)。
个别研究对不同的潜在混杂因素进行了调整,且有1项研究仅提供了未调整的数据。无法排除发表偏倚或结果的选择性报告。
亚临床甲状腺功能减退和亢进可能与冠心病和死亡率的适度风险增加相关,合并高质量研究时风险估计值较低,亚临床甲状腺功能亢进的置信区间较大。